Category Archives: Clinical Cardiology

La Porte and Starke Hospitals have announced their 2019 selections for Colleagues of the Year La Porte and Starke Hospitals have announced their 2019 selections for Colleagues of the Year, honoring individuals who were nominated both by patients and their peers for providing excellent, compassionate care and service to the community. Continue reading →

University of Maryland Shore Regional Health experienced significant progress in 2019 toward achieving our mission, "Creating Healthier Communities Together," and our vision, "To Be the Regions Leader in Patient Centered Health Care." As in years past, the amazing talent, steadfast commitment and highly engaged teamwork of the nearly 3,000 members of our UM SRH family enabled us to move forward in each of our key goals. Quality, Safety and Patient Experience Delivering a positive patient experience is our guiding principle at UM SRH. This is only possible in a healthy and collegial workplace environment Continue reading →

January 06, 2020 12:05 ET | Source: Novartis International AG Basel, January 6, 2020 Novartis AG (NYSE: NVS) (Novartis) today announced that it has completed the acquisition of The Medicines Company (the Company) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (Purchaser), with and into the Company, with the Company surviving the merger, without a vote of the Companys stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. In the merger, each share of the Companys common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Purchaser, the Company, any other subsidiary of Novartis or any subsidiary of the Company, or shares that are held in the Companys treasury or shares held by any Company stockholder who has properly demanded and perfected appraisal rights under Delaware law) has been converted into the right to receive USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding Continue reading →

This transcript has been edited for clarity. Hi, my name is Mamas Mamas. I'm professor of cardiology at Keele University, and welcome to Medscape. Continue reading →

As the use of edge-to-edge repair of mitral regurgitation (MR) ramps up, an expert consensus statement proposes volume standards, as well as operator and institutional requirements for all institutions providing treatment of mitral valve (MV) disease via transcatheter techniques. "These recommendations attempt to balance the need to support optimal quality outcomes with the goal of facilitating access to such innovative therapies an important paradigm for the development and implementation of future, less invasive approaches to structural heart disease," the writing committee states. Adherence to these recommendations, they say, will "maximize the chances that these therapies will be successfully incorporated into management pathways for patients with MV disease in the United States." The recommendations, published online December 16 in the Journal of the American College of Cardiology, are a joint effort of the American Association for Thoracic Surgery (AATS), the American College of Cardiology (ACC), the Society for Cardiovascular Angiography and Interventions (SCAI), and the Society of Thoracic Surgeons (STS). Continue reading →

................................ Continue reading →

InfoBionic was awarded the 2019 Frost and Sullivan North American Remote Cardiac Monitoring Technology Leadership Award for a reason: their cutting-edge technology and remarkable overall performance with full disclosure monitoring. As the year comes to a close, CEO Stuart Long looks ahead to additional product enhancements and the future of cardiac monitoring, building on the success of advancements realized this year Continue reading →

As more patients with cancer survive, the risk of cardiac complications due to the effects of therapies has become a concern to oncologists and cardiologists alike. Continue reading →

Long-term follow-up of the CvLPRIT trial shows that the risk of major adverse cardiovascular events continues to favor STEMI patients with obstructive multivessel disease who underwent complete revascularization compared with patients who had PCI of the culprit lesion only. Complete revascularization also was associated with a lower risk death and MI, with investigators reporting that after a median follow-up of 5.6 years, 10.0% of STEMI patients who underwent complete revascularization died or had an MI compared with 18.5% of patients randomized to PCI of the infarct-related artery alone (P < 0.0175). Continue reading →

Black patients are less likely than white patients to take low-dose aspirin for primary prevention of cardiovascular disease, observational data on more than 65,000 people show. As has previously been shown in earlier studies focused on different populations, though, aspirin didnt appear to have a protective effect in black individuals. The drug was once the mainstay of preventive regimens for CVD Continue reading →